Bone metastases detection by circulating biomarkers: OPG and RANK-L

Laura Mercatali, Toni Ibrahim, Emanuele Sacanna, Emanuela Flamini, Emanuela Scarpi, Daniele Calistri, Marianna Ricci, Patrizia Serra, Rossana Ricci, Wainer Zoli, Yibin Kang, Dino Amadori

Research output: Contribution to journalArticlepeer-review


Osteoprotegerin (OPG) is a decoy receptor of the receptor activator of nuclear factor-κB ligand (RANK-L) and plays an important role in the formation of metastatic bone lesions. We evaluated the usefulness of circulating OPG and RANK-L for the detection of bone metastases. We enrolled 143 individuals in the study: 30 healthy donors (HD) and 113 breast cancer patients. Among patients, 49 had no evidence of disease (NEDP), 54 had bone metastases (BMP) at first diagnosis, and 10 had visceral metastases (VMP). Both transcripts were determined in peripheral blood samples using quantitative PCR. Receiver operating characteristic (ROC) curve analysis was used to calculate the diagnostic accuracy of OPG, RANK-L, CEA and CA15-3. OPG and RANK-L median values were significantly lower in BMP (median 0.5, range 0.1-5.7, p

Original languageEnglish
Pages (from-to)255-261
Number of pages7
JournalInternational Journal of Oncology
Issue number1
Publication statusPublished - Jul 2011


  • Bone metastases
  • Breast cancer
  • Diagnosis
  • Osteoprotegerin
  • Receptor activator of nuclear factor-κB ligand

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Bone metastases detection by circulating biomarkers: OPG and RANK-L'. Together they form a unique fingerprint.

Cite this